{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:12:29Z","timestamp":1788772349558,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer associated with early metastasis and poor outcomes in the advanced stages. Immune checkpoint inhibitors (ICIs), particularly avelumab, represent the first\u2010line therapy for metastatic MCC. However, effective treatment options after progression or intolerance remain limited. Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has emerged as a potential therapeutic option for tumors expressing somatostatin receptors (SSTRs). We present three patients with advanced MCC (aged 73, 45, and 77\u2009years, respectively) treated with\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010oxodotreotide after failure or intolerance of ICI therapy and cytotoxic chemotherapy.\n                    <jats:sup>111<\/jats:sup>\n                    In pentetreotide single photon emission computed tomography\/computed tomography demonstrated SSTR uptake in all patients, supporting the rationale for PRRT. All patients ultimately experienced disease progression; however, one achieved transient disease stabilization with tumor reduction. The times from the first PRRT administration to death were 3.4, 4.2, and 1.4\u2009months, respectively. No serious treatment\u2010related adverse events were observed. These findings suggest that\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010oxodotreotide may represent a feasible and relatively safe option for patients with treatment\u2010refractory MCC, although its antitumor efficacy is limited. However, further prospective studies are required to elucidate its clinical role.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.70495","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:02:11Z","timestamp":1788771731000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three Cases of Merkel Cell Carcinoma Treated With Lutetium\u2010177 Oxodotreotide"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1566-1274","authenticated-orcid":false,"given":"Michitoshi","family":"Kurisaki","sequence":"first","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-8182","authenticated-orcid":false,"given":"Eiji","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4648-035X","authenticated-orcid":false,"given":"Yoshiki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Kase","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-1732","authenticated-orcid":false,"given":"Harutaka","family":"Seshimo","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kage","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-7100","authenticated-orcid":false,"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"},{"name":"Department of Dermatology, Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-6767","authenticated-orcid":false,"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical Characteristics of Merkel Cell Carcinoma at Diagnosis in 195 Patients: The AEIOU Features","volume":"58","author":"Heath M.","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.6004\/jnccn.2018.0055","article-title":"Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Bichakjian C. K.","year":"2018","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100755","article-title":"Clinical Characteristics and Treatments of Merkel Cell Carcinoma in Japan: A Multi\u2010Center Retrospective Study","volume":"3","author":"Nakano E.","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel Cell Carcinoma","volume":"3","author":"Becker J. C.","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in Patients With Chemotherapy\u2010Refractory Metastatic Merkel Cell Carcinoma: A Multicentre, Single\u2010Group, Open\u2010Label, Phase 2 Trial","volume":"17","author":"Kaufman H. L.","year":"2016","journal-title":"Lancet Oncology"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103461"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu\u2010Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg J.","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_9_1","first-page":"1696","article-title":"Long\u2010Term Efficacy, Survival, and Safety of 177Lu\u2010DOTATATE in Patients With Gastroenteropancreatic Neuroendocrine Tumors","volume":"35","author":"Brabander T.","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_10_1","first-page":"3278","article-title":"Long\u2010Term Tolerability of PRRT in Neuroendocrine Tumors: Is There a Risk of Secondary Hematologic Malignancies?","volume":"121","author":"Bodei L.","year":"2015","journal-title":"Cancer"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381062"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1148\/rg.2019190102","article-title":"Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know","volume":"39","author":"Akaike G.","year":"2019","journal-title":"Radiographics"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2967\/jnmt.122.264904","article-title":"Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review","volume":"51","author":"Askari E.","year":"2023","journal-title":"Journal of Nuclear Medicine Technology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2967\/jnumed.121.262344","article-title":"Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy With Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma","volume":"63","author":"Ferdinandus J.","year":"2022","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_9_15_1","first-page":"1327","article-title":"Combination of Peptide Receptor Radionuclide Therapy and Immune Checkpoint Inhibitors: A Novel Therapeutic Approach","volume":"47","author":"Kim Y. J.","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2967\/jnmt.119.237354","article-title":"Combined 177 Lu\u2010DOTATATE Peptide Receptor Radionuclide Therapy and Platinum\u2010Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option","volume":"48","author":"Adnan A.","year":"2020","journal-title":"Journal of Nuclear Medicine Technology"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:02:14Z","timestamp":1788771734000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":15,"alternative-id":["10.1111\/1346-8138.70495"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70495","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2026-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1346-8138.70495"}}